Skip to main content

Table 1 Main clinical data in overall EC population and in EC patients categorized according to rs4430794 genotypes

From: HNF1B polymorphism influences the prognosis of endometrial cancer patients: a cohort study

Characteristic Patients (n.) rs4430796 Pvalue
   GG (n. %) GA/AA (n. %)  
  191 57 134  
Age 1 64.3 ± 10.6 64.9 ± 10.1 64.0 ± 10.8  
Histological type     
Type I 162 46 (28.4) 116 (71.6)  
Type II 2 29 11 (37.9) 18 (62.1) 0.304
Figo stage 2     
I 152 45 (29.6) 107 (70.4)  
II 12 4 (33.3) 8 (66.7)  
III 23 6 (26.1) 17 (73.9)  
IV 4 2 (50.0) 2 (50.0) 0.820
Grading (for Type I)     
G1 70 17 (24.3) 53 (75.7)  
G2 63 18 (28.6) 45 (71.4)  
G3 29 11 (37.9) 18 (62.1) 0.186
Myometrial invasion     
<50% 100 30 (30.0) 70 (70.0)  
>50% 91 27 (29.7) 64 (70.3) 0.960
Lymph node metastasis (129 lymphadenectomy)     
No 113 34 (30.1) 79 (69.9)  
Yes 16 4 (25.0) 12 (75.0) 0.677
Adjuvant treatment     
None 119 36 (27.9) 83 (64.3)  
Radiotherapy 42 12 (28.6) 30 (71.4)  
Chemo-Radiotherapy 30 9 (30.0) 21 (70.0) 0.926
Radiotherapy (42 patients)     
External beam therapy 2 1 (50.0) 1 (50.0)  
Brachytherapy 21 6 (28.6) 15 (71.4)  
Combined 19 5 (26.3) 14 (73.7) 0.615
  1. 1 Age (years) is shown as mean ± SD.
  2. 2 Staging and grading were done according to the 2009 International Federation of Gynecology and Obstetrics (FIGO) classifications [23]. Women treated before 2009 were restaged according to the 2009 FIGO classifications.